Evaluating depression and anxiety in chemotherapy patients
Evaluation of Depression and Anxiety in Chemotherapy Patients
This study looks at how common and serious depression and anxiety are in people starting chemotherapy compared to those who are on later cycles to help improve care for cancer patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 89 Years |
| Sex | All |
| Sponsor | Richmond University Medical Center Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 3 sites (Staten Island, New York and 2 other locations) |
| Trial ID | NCT03552731 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the prevalence and severity of depression and anxiety among patients undergoing chemotherapy at Richmond University Medical Center. Participants currently receiving their initial chemotherapy cycle will be compared to those undergoing subsequent cycles. Data will be collected using standardized scales, including the Generalized Anxiety Disorder 7-item Scale (GAD7) and the Patient Health Questionnaire (PHQ9), alongside demographic information from medical records. The goal is to better understand the psychological distress experienced by cancer patients to improve screening and treatment options.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with a confirmed diagnosis of solid tumors or hematologic cancers who are currently undergoing chemotherapy.
Not a fit: Patients who have a previous diagnosis of anxiety or depression prior to chemotherapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved screening and treatment for depression and anxiety in cancer patients, potentially enhancing their overall outcomes.
How similar studies have performed: While studies have shown that anxiety and depression negatively impact cancer outcomes, this specific evaluation of their prevalence in chemotherapy patients is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria:1)Patients (greater than equal to) 18 years of age 2)Patients with a confirmed diagnosis of a solid tumor or hematologic cancer 3)Patients who are able to understand the informed consent and read the selfadministered metrics. 4)Patients undergoing chemotherapy. - Exclusion Criteria: * Patients unable to give informed consent. * Patients with a previous diagnosis of anxiety or depression prior to chemotherapy
Where this trial is running
Staten Island, New York and 2 other locations
- Richmond University Medical Center — Staten Island, New York, United States (Recruiting)
- Richmond University Medical Center — Staten Island, New York, United States (Recruiting)
- Richmond University Medical Center — Staten Island, New York, United States (Recruiting)
Study contacts
- Study coordinator: Dennis Bloomfield, MD
- Email: dbloomfield@rumcsi.org
- Phone: 718-818-2707
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.